Oxidative stress from reflux esophagitis to esophageal cancer: the alleviation with antioxidants

References

• Oh TY, Lee JS, Ahn BO, Cho H, Kim WB, Kim YB, et al. Oxidative stress is more important than acid in the pathogenesis of reflux oesophagitis in rats. Gut 2001;49:364–371.
   PubMed Web of Science ®Google Scholar
• Oh TY, Lee JS, Ahn BO, Cho H, Kim WB, Kim YB, et al. Oxidative damages are critical in pathogenesis of reflux esophagitis: implication of antioxidants in its treatment. Free Radic Biol Med 2001;30:905–915.
   PubMed Web of Science ®Google Scholar
• Inayama M, Hashimoto N, Tokoro T, Shiozaki H. Involvement of oxidative stress in experimentally induced reflux esophagitis and esophageal cancer. Hepatogastroenterology 2007;54:761–765.
   PubMed Web of Science ®Google Scholar
• Li Y, Martin RC, 2nd. Reflux injury of esophageal mucosa: experimental studies in animal models of esophagitis, Barrett’s esophagus and esophageal adenocarcinoma. Dis Esophagus 2007;20:372–378.
   PubMed Web of Science ®Google Scholar
• Arora Z, Garber A, Thota PN. Risk factors for Barrett’s esophagus. J Dig Dis 2016. [Epub ahead of print]. doi: 10.1111/1751-2980.12332.
   PubMed Web of Science ®Google Scholar
• Souza RF, Krishnan K, Spechler SJ. Acid, bile, and CDX: the ABCs of making Barrett’s metaplasia. Am J Physiol Gastrointest Liver Physiol 2008;295:G211–G218.
   Google Scholar
• Colleypriest BJ, Farrant JM, Slack JM, Tosh D. The role of Cdx2 in Barrett’s metaplasia. Biochem Soc Trans 2010;38:364–369.
   PubMed Web of Science ®Google Scholar
• Colleypriest BJ, Ward SG, Tosh D. How does inflammation cause Barrett’s metaplasia? Curr Opin Pharmacol 2009;9:721–726.
   PubMed Web of Science ®Google Scholar
• Tamagawa Y, Ishimura N, Uno G, Yuki T, Kazumori H, Ishihara S, et al. Notch signaling pathway and Cdx2 expression in the development of Barrett’s esophagus. Lab Invest 2012;92:896–909.
   PubMed Web of Science ®Google Scholar
• Slack JM, Colleypriest BJ, Quinlan JM, Yu WY, Farrant MJ, Tosh D. Barrett’s metaplasia: molecular mechanisms and nutritional influences. Biochem Soc Trans 2010;38:313–319.
   PubMed Web of Science ®Google Scholar
• Baruah A, Buttar N, Chandra R, Chen X, Clemons NJ, Compare D, et al. Translational research on Barrett’s esophagus. Ann N Y Acad Sci 2014;1325:170–186.
   PubMed Web of Science ®Google Scholar
• Morita S, Matsumoto Y, Okuyama S, Ono K, Kitamura Y, Tomori A, et al. Bile acid-induced expression of activation-induced cytidine deaminase during the development of Barrett’s oesophageal adenocarcinoma. Carcinogenesis 2011;32:1706–1712.
   PubMed Web of Science ®Google Scholar
• Guy NC, Garewal H, Holubec H, Bernstein H, Payne CM, Bernstein C, et al. A novel dietary-related model of esophagitis and Barrett’s esophagus, a premalignant lesion. Nutr Cancer 2007;59:217–227.
   PubMed Web of Science ®Google Scholar
• Olliver JR, Hardie LJ, Gong Y, Dexter S, Chalmers D, Harris KM, Wild CP. Risk factors, DNA damage, and disease progression in Barrett’s esophagus. Cancer Epidemiol Biomarkers Prev 2005;14:620–625.
   PubMed Web of Science ®Google Scholar
• Atherfold PA, Jankowski JA. Molecular biology of Barrett’s cancer. Best Pract Res Clin Gastroenterol 2006;20:813–827.
   PubMed Web of Science ®Google Scholar
• Pera M, Brito MJ, Poulsom R, Riera E, Grande L, Hanby A, Wright NA. Duodenal-content reflux esophagitis induces the development of glandular metaplasia and adenosquamous carcinoma in rats. Carcinogenesis 2000;21:1587–1591.
   PubMed Web of Science ®Google Scholar
• Wang DH, Clemons NJ, Miyashita T, Dupuy AJ, Zhang W, Szczepny A, et al. Aberrant epithelial-mesenchymal Hedgehog signaling characterizes Barrett’s metaplasia. Gastroenterology 2010;138:1810–1822.
   PubMed Web of Science ®Google Scholar
• Dvorak K, Payne CM, Chavarria M, Ramsey L, Dvorakova B, Bernstein H, et al. Bile acids in combination with low pH induce oxidative stress and oxidative DNA damage: relevance to the pathogenesis of Barrett’s oesophagus. Gut 2007;56:763–771.
   PubMed Web of Science ®Google Scholar
• Jabri MA, Tounsi H, Rtibi K, Marzouki L, Sakly M, Sebai H. Ameliorative and antioxidant effects of myrtle berry seed (Myrtus communis) extract during reflux-induced esophagitis in rats. Pharm Biol 2016. [Epub ahead of print]. doi: 10.3109/13880209.2015.1107748.
   PubMed Web of Science ®Google Scholar
• Kwon OJ, Choo BK, Lee JY, Kim MY, Shin SH, Seo BI, et al. Protective effect of Rhei Rhizoma on reflux esophagitis in rats via Nrf2-mediated inhibition of NF-κB signaling pathway. BMC Complement Altern Med 2016;16:7.
   PubMed Web of Science ®Google Scholar
• Giri AK, Rawat JK, Singh M, Gautam S, Kaithwas G. Effect of lycopene against gastroesophageal reflux disease in experimental animals. BMC Complement Altern Med 2015;15:110.
   PubMedGoogle Scholar
• Kang JW, Lee SM. Protective effects of chlorogenic acid against experimental reflux esophagitis in rats. Biomol Ther (Seoul) 2014;22:420–425.
   PubMed Web of Science ®Google Scholar
• Zamora Z, Molina V, Mas R, Ravelo Y, Perez Y, Oyarzabal A. Protective effects of D-002 on experimentally induced gastroesophageal reflux in rats. World J Gastroenterol 2014;20:2085–2090.
   PubMed Web of Science ®Google Scholar
• Brzozowska I, Strzalka M, Drozdowicz D, Konturek SJ, Brzozowski T. Mechanisms of esophageal protection, gastroprotection and ulcer healing by melatonin. implications for the therapeutic use of melatonin in gastroesophageal reflux disease (GERD) and peptic ulcer disease. Curr Pharm Des 2014;20:4807–4815.
   PubMed Web of Science ®Google Scholar
• Appelman HD, Matejcic M, Parker MI, Riddell RH, Salemme M, Swanson PE, Villanacci V. Progression of esophageal dysplasia to cancer. Ann N Y Acad Sci 2014;1325:96–107.
   PubMed Web of Science ®Google Scholar
• Feagins LA, Souza RF. Molecular targets for treatment of Barrett’s esophagus. Dis Esophagus 2005;18:75–86.
   PubMed Web of Science ®Google Scholar
• Picardo SL, Maher SG, O’Sullivan JN, Reynolds JV. Barrett’s to oesophageal cancer sequence: a model of inflammatory-driven upper gastrointestinal cancer. Dig Surg 2012;29:251–260.
   PubMed Web of Science ®Google Scholar
• Lee JS, Oh TY, Ahn BO, Cho H, Kim WB, Kim YB, et al. Involvement of oxidative stress in experimentally induced reflux esophagitis and Barrett’s esophagus: clue for the chemoprevention of esophageal carcinoma by antioxidants. Mutat Res 2001;480–481:189–200.
   PubMed Web of Science ®Google Scholar
• Zeb MH, Baruah A, Kossak SK, Buttar NS. Chemoprevention in Barrett’s esophagus: current status. Gastroenterol Clin North Am 2015;44:391–413.
   PubMed Web of Science ®Google Scholar
• Dunbar KB, Souza RF, Spechler SJ. The effect of proton pump inhibitors on Barrett’s esophagus. Gastroenterol Clin North Am 2015;44:415–424.
   PubMed Web of Science ®Google Scholar
• Miyashita T, Shah FA, Harmon JW, Marti GP, Matsui D, Okamoto K, et al. Do proton pump inhibitors protect against cancer progression in GERD? Surg Today 2013;43:831–837.
   PubMed Web of Science ®Google Scholar
• Woodall CE, Li Y, Liu QH, Wo J, Martin RC. Chemoprevention of metaplasia initiation and carcinogenic progression to esophageal adenocarcinoma by resveratrol supplementation. Anticancer Drugs 2009;20:437–443.
   PubMed Web of Science ®Google Scholar
• Martin RC, Liu Q, Wo JM, Ray MB, Li Y. Chemoprevention of carcinogenic progression to esophageal adenocarcinoma by the manganese superoxide dismutase supplementation. Clin Cancer Res 2007;13:5176–5182.
   PubMed Web of Science ®Google Scholar
• Akiyama J, Komanduri S, Konda VJ, Mashimo H, Noria S, Triadafilopoulos G. Endoscopy for diagnosis and treatment in esophageal cancers: high-technology assessment. Ann N Y Acad Sci 2014;1325:77–88.
   PubMed Web of Science ®Google Scholar
• Nguyen T, Duan Z, Naik AD, Kramer JR, El-Serag HB. Statin use reduces risk of esophageal adenocarcinoma in US veterans with Barrett’s esophagus: a nested case-control study. Gastroenterology 2015;149:1392–1398.
   PubMed Web of Science ®Google Scholar
• Nguyen DM, Richardson P, El-Serag HB. Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett’s esophagus. Gastroenterology 2010;138:2260–2266.
   PubMed Web of Science ®Google Scholar
• Beales IL, Vardi I, Dearman L. Regular statin and aspirin use in patients with Barrett’s oesophagus is associated with a reduced incidence of oesophageal adenocarcinoma. Eur J Gastroenterol Hepatol 2012;24:917–923.
   PubMed Web of Science ®Google Scholar
• Masclee GM, Coloma PM, Spaander MC, Kuipers EJ, Sturkenboom MC. NSAIDs, statins, low-dose aspirin and PPIs, and the risk of oesophageal adenocarcinoma among patients with Barrett’s oesophagus: a population-based case-control study. BMJ Open 2015;5:e006640.
   Web of Science ®Google Scholar
• Reid BJ, Li X, Galipeau PC, Vaughan TL. Barrett’s oesophagus and oesophageal adenocarcinoma: time for a new synthesis. Nat Rev Cancer 2010;10:87–101.
   PubMed Web of Science ®Google Scholar
• Baruah A, Buttar NS. Chemoprevention in Barrett’s oesophagus. Best Pract Res Clin Gastroenterol 2015;29:151–165.
   PubMed Web of Science ®Google Scholar